Landscape of somatic single nucleotide variants and indels in colorectal cancer and impact on survival

  • Syed H Zaidi
  • Tabitha A Harrison
  • Amanda I Phipps
  • Robert Steinfelder
  • Quang M Trinh
  • Conghui Qu
  • Barbara L Banbury
  • Peter Georgeson
  • Catherine S Grasso
  • Marios Giannakis
  • Jeremy B Adams
  • Elizabeth Alwers
  • Efrat L Amitay
  • Richard T Barfield
  • Sonja I Berndt
  • Ivan Borozan
  • Hermann Brenner
  • Stefanie Brezina
  • Daniel D Buchanan
  • Yin Cao
  • Andrew T Chan
  • Jenny Chang-Claude
  • Charles M Connolly
  • David A Drew
  • Alton Brad Farris
  • Jane C Figueiredo
  • Amy J French
  • Charles S Fuchs
  • Levi A Garraway
  • Steve Gruber
  • Mark A Guinter
  • Stanley R Hamilton
  • Sophia Harlid
  • Lawrence E Heisler
  • Akihisa Hidaka
  • John L Hopper
  • Wen-Yi Huang
  • Jeroen R Huyghe
  • Mark A Jenkins
  • Paul M Krzyzanowski
  • Mathieu Lemire
  • Yi Lin
  • Xuemei Luo
  • Elaine R Mardis
  • John D McPherson
  • Jessica K Miller
  • Victor Moreno
  • Xinmeng Jasmine Mu
  • Reiko Nishihara
  • Nickolas Papadopoulos
  • Danielle Pasternack
  • Michael J Quist
  • Adilya Rafikova
  • Emma E G Reid
  • Eve Shinbrot
  • Brian H Shirts
  • Lincoln D Stein
  • Cherie D Teney
  • Lee Timms
  • Caroline Y Um
  • Bethany Van Guelpen
  • Megan Van Tassel
  • Xiaolong Wang
  • David A Wheeler
  • Christina K Yung
  • Li Hsu
  • Shuji Ogino
  • Andrea Gsur
  • Polly A Newcomb
  • Steven Gallinger
  • Michael Hoffmeister
  • Peter T Campbell
  • Stephen N Thibodeau
  • Wei Sun
  • Thomas J Hudson

Related Research units

Abstract

Colorectal cancer (CRC) is a biologically heterogeneous disease. To characterize its mutational profile, we conduct targeted sequencing of 205 genes for 2,105 CRC cases with survival data. Our data shows several findings in addition to enhancing the existing knowledge of CRC. We identify PRKCI, SPZ1, MUTYH, MAP2K4, FETUB, and TGFBR2 as additional genes significantly mutated in CRC. We find that among hypermutated tumors, an increased mutation burden is associated with improved CRC-specific survival (HR = 0.42, 95% CI: 0.21-0.82). Mutations in TP53 are associated with poorer CRC-specific survival, which is most pronounced in cases carrying TP53 mutations with predicted 0% transcriptional activity (HR = 1.53, 95% CI: 1.21-1.94). Furthermore, we observe differences in mutational frequency of several genes and pathways by tumor location, stage, and sex. Overall, this large study provides deep insights into somatic mutations in CRC, and their potential relationships with survival and tumor features.

Bibliographical data

Original languageEnglish
ISSN2041-1723
DOIs
Publication statusPublished - 20.07.2020
PubMed 32686686